UNSPSC 51383904: Nifenazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H16N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8780F0K71U, chemically known as 2,3-dimethyl-4-nicotinamido-1-phenyl-3-pyrazolin-5-on but generally known as nifenazone, which bears US NIH Compound Identifier 4487. European Medicines Agency schedules Nifenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09256MIG. The term NIFENAZONE is an International Non-Proprietary Name.

UNSPSC 51383904 Nifenazone is a Commodity code, but the recent state and local procurement activity tagged under it does not reflect pharmaceutical nifenazone procurement; instead, Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB, reflecting a mismatch between the code's nominal scope and what is actually being bought. The code shows minimal relevant recent activity for state and local buyers pursuing pharmaceutical and medical supply procurement aligned with the nifenazone product line.

Seminole County's June 2026 posting (IFB60459723LAS, response deadline July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The county required electronic bid submission through its e-Procurement Portal, with vendors responsible for all shipping and delivery costs; the contract offered a two-year initial term with an optional one-year renewal and included a three-month probationary termination clause. Vendors had to meet drug-free workplace certification, E-Verify compliance, and workers' compensation and commercial general liability insurance requirements. The procurement may have been funded through FEMA and carried corresponding federal compliance obligations. Because this single recent opportunity does not represent a pattern of nifenazone-specific procurement and the code appears misaligned with actual state and local buying in this category, firms evaluating the code should confirm current purchasing activity directly with issuing bodies before pursuing nifenazone supply contracts under this classification.